Drug news
CHMP recommends Dificlir for Clostrium difficile
The CHMP recommends European marketing authorisation for the first in class antibiotic Dificlir (fidaxomicin, known as Dificid in the USA) from Astellas/Optimer Pharma. The authorisation is for Clostridium difficile. The FDA had approved Dificid for the treatment of C. difficile-associated diarrhoea in May 2011. Astellas have the European rights
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.